Belite Bio, Inc
BLTE
Classifica tra le azioni
#2975
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Prezzo delle azioni
$154.49
Capitalizzazione di mercato
$6.22B
Variazione (1 giorno)
0.02%
Variazione (1 anno)
67.92%
Paese
US
Scambia Belite Bio, Inc (BLTE)
Categoria
Healthcare
Storico del prezzo dell'azione per Belite Bio, Inc (BLTE)
Prezzo di chiusura più alto: $154.35 il 2026-10-01
Prezzo di chiusura più basso: $10.59 il 2022-04-01
Prezzo di chiusura più basso: $10.59 il 2022-04-01
Storico del prezzo dell'azione di Belite Bio, Inc dal 2022 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | 1.18% |
| 2025 | 137.93% |
| 2024 | 45.90% |
| 2023 | 43.40% |
| 2022 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $517.48 | 21.40% |
US
|
|
| $248.12 | 802.58% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $884.85 | 6.00% |
NL
|
|
| $752.87 | 7.40% |
CH
|
